Page Hospital has decided to not allow mothers to vaginally deliver their babies if the mother has had a cesarean in the past. I would be one of the affected patients. In February 2002, I had an uncomplicated vaginal delivery. In February of 2004, an emergency cesarean was necessary because of placental abruption. In December of 2007, I delivered a healthy 8+ lb baby boy at Page Hospital by VBAC. I received strong pressure from the hospital staff encouraging a repeat cesarean, but delivered vaginally in spite of the effort. Having had a successful VBAC since my cesarean, I don’t find any medical need for an elective cesarean for my current pregnancy. I am wary of having a surgery with no medical indication for it. I am sure it would not be ethical.
If the concern is for legal liability, the logic is flawed. If I desired a VBAC in this community whose hospital has adopted the ACOG standard, effectively denying me a VBAC, and if my cesarean birth resulted in harm to me or to my baby, I would have very strong legal standing to bring a lawsuit (for example, the Meador vs Stahler and Gheridian case in Massachusetts).
I found out about this hospital’s VBAC ban at my August OB appointment, and set about fighting it right away. I wrote a letter to the hospital, explaining my arguments about VBAC. As I was driving, I heard there was a meeting of the Board of Directors that same night. I printed out several copies of the letter, printed up supporting research and documentation, and presented everyone at the board meeting with a copy of the whole thing. I was called a few days later to have a meeting with the CEO, Sandy Haryasz. I met with her. She told me that she was an RN who had worked in L&D for many years.
I was very polite and discussed my situation with her and told her that my risk of major complications was about the same as a first time moms. She listened very sweetly and agreed that I was a great candidate for a successful VBAC. She offered to help as best as she can to find me another place to deliver. I reminded her that the next closest hospital in Arizona, Flagstaff Medical Center, also has banned VBAC. She was recommending I go to Dixie Hospital in St. George, Utah. We ended the meeting very politely.
I thought for a bit, had some unanswered questions, so called Sandy’s office again to schedule another appointment. At this meeting I asked why they are doing labor and delivery if they cannot offer a timely cesarean. She defended the hospital, saying that they can do emergency cesaereans, but did not want to accept the risk of VBAC. I asked what the hospital policy is if I show up and just refuse to consent to a cesarean. She said they would seek a court order. She repeated to me that Page Hospital does not have the facilities nessasary to handle an emergency.
At my September OB appointment, I told my doctor what I had been up to. He was filled with apathy. He was wringing his hands, and said he would have to do it if the hospital told him he had to. He told me he would lose his licence if he didn’t. I have looked into it and have yet to find where doctors lose their licence for having ethics. But it was clear to me that I was not safe in this hospital, and if I step foot in the building, I would have a cesarean, and my doctor would do it while I scream in protest.
I have decided I will have to go to Phoenix, where I might have a place to stay. I used to live down there and know the area. I will be having a consult with an OB, and hopefully that will go well.
Our ward choir sang this great hymn, a personal favorite, in sacrament meeting today. We set the goal to sing in the choir as a family and so Paul and I sang with Jeff, Andy, and Allison while Ben sat and watched. It was fun to sing with so many family members, as well as a large group from our ward. We sang a really awesome acapella shaker version of this hymn, can’t seem to find it on the web, but here are the lyrics:
How firm a foundation, ye saints of the Lord,
Is laid for your faith in His excellent Word!
What more can He say than to you He hath said,
You, who unto Jesus for refuge have fled?
In every condition, in sickness, in health;
In poverty’s vale, or abounding in wealth;
At home and abroad, on the land, on the sea,
As thy days may demand, shall thy strength ever be.
Fear not, I am with thee, O be not dismayed,
For I am thy God and will still give thee aid;
I’ll strengthen and help thee, and cause thee to stand
Upheld by My righteous, omnipotent hand.
When through the deep waters I call thee to go,
The rivers of woe shall not thee overflow;
For I will be with thee, thy troubles to bless,
And sanctify to thee thy deepest distress.
When through fiery trials thy pathways shall lie,
My grace, all sufficient, shall be thy supply;
The flame shall not hurt thee; I only design
Thy dross to consume, and thy gold to refine.
Even down to old age all My people shall prove
My sovereign, eternal, unchangeable love;
And when hoary hairs shall their temples adorn,
Like lambs they shall still in My bosom be borne.
The soul that on Jesus has leaned for repose,
I will not, I will not desert to its foes;
That soul, though all hell should endeavor to shake,
I’ll never, no never, no never forsake.
And here is a video I made with this hymn as the background mysic:
Will the Health Care Bill mandate all of us being chipped? From Veri-Chips website:
VeriMed Health Link
“Health Link is the connection between you and your personal health record. Health Link utilizes a tiny, passive microchip (the first and only microchip cleared for patient identification by the FDA) and a secure online database that links you to your personal health record.”
We, the people, will not be microchipped, numbered, tracked or controlled by biometric encryption and satellite tracking devices, by the use of IBM mainframe computers and Verichip technology, set up by the WHO/UN/EU banksters and their agent governments and “royal families” for our total enslavement.
We, the people, have a spirit of our own, a mind of our own, a soul of our own and it is not all our own because it is joined to a force beyond us, as Patrick McGoohan, the actor who played “The Prisoner” trapped in the totalitarian environment of the “Village” said.
Check out this documentary that throws light on the secret agenda to inject nanochips and RFID tracking devices into people by means of the use of the “swine flu” jab needle called:
IBM and Verichip – The Human Microchipping Agenda
One Mainframe To Rule Them All is a breathtaking rundown of the human microchipping agenda. Concise and effective, it breaks down the coming global information control grid in all its horrifying detail. Scarier than any horror movie could be because it is real and documented.
VeriChip Corporation (”VeriChip”) (NASDAQ:CHIP) and its development partner RECEPTORS LLC (“RECEPTORS”), a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding products, announced today they will host an event for the medical, patient and investor communities on October 22, 2009, in New York to unveil details of their virus triage detection system for the H1N1 virus and Phase II development of an in vivo glucose-sensing RFID microchip. The companies will also provide a product demonstration of the virus triage detection system currently being developed.
The event will take place at the Grand Hyatt at 4:30 p.m. ET and feature a presentation by Robert E. Carlson, Ph.D., President and Chief Science Officer of RECEPTORS LLC, and an expert in the field of proteomics and the development of artificial receptors. Parties interested in attending the New York event should contact Allison Tomek at (561) 805-8008 or at atomek@verichipcorp.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it as soon as possible. Space is limited and registration will be accepted on a first-come, first-served basis.
The virus triage detection system is intended to initially provide two levels of identification within minutes. Once developed, utilizing a simple test tube or strip device format that can be combined with an inexpensive reader, it is expected that the first level will prep the sample and identify the agent as a flu or non-flu virus, and the second level will sub-type (e.g. H1N1) classify the flu virus and alert the user to the presence of pandemic threat viruses. Additionally, VeriChip believes the influenza triage diagnostic system will be scalable and will be able to be rapidly adapted to identify new strains of influenza and other viruses as they evolve, giving the virus triage detection system value for future testing applications in healthcare.
VeriChip previously announced in November 2008 that RECEPTORS completed Phase I of the project, which demonstrated the proof-of-concept foundation of the glucose-sensing system. The companies expect Phase II will demonstrate a glucose concentration response in the presence of blood and interstitial fluid matrix components. The companies published a white paper entitled, “Development of an Implantable Glucose Sensor,” which outlines the product’s development and is available at www.verichipcorp.com. About RECEPTORS LLC
RECEPTORS LLC develops SMART MATERIALS products for laboratory, clinical, industrial hygiene and healthcare use that selectively capture and measure chemical, biochemical and cellular targets from complex biological, environmental or industrial samples. The Company’s patented AFFINITY by DESIGN™ platform has broad applicability, ranging from the isolation of disease pathway proteins for drug discovery and production of therapeutic antibodies, to the capture of bacteria and viruses for disinfection and diagnostic purposes. RECEPTORS LLC is a private company based in suburban Minneapolis, Minnesota. For further information please visit http://www.receptorsllc.com. About VeriChip Corporation
VeriChip Corporation, headquartered in Delray Beach, Florida, has developed the VeriMed™ Health Link System for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip and corresponding personal health record, cleared for medical use in October 2004 by the United States Food and Drug Administration.
On September 8, 2009, VeriChip Corporation announced it agreed to acquire Steel Vault Corporation (OTCBB:SVUL) to form PositiveID Corporation. PositiveID will provide identification technologies and tools to protect consumers and businesses. The companies expect the merger to close in the fourth quarter of 2009.
For more information on VeriChip, please call 1-800-970-2447, or e-mail info@verichipcorp.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it . Additional information can be found online at www.verichipcorp.com.
Statements about VeriChip’s future expectations, including its development of a triage detection system, the expectation that the triage detection system, if developed, will function as intended, including the ability to provide two levels of identification within minutes, and be a marketable product, the belief that the influenza triage diagnostic system will be scalable and will be able to be rapidly adapted to identify new strains of influenza and other viruses as they evolve, giving the virus detection triage system value for future testing applications in healthcare, the expectation that Phase II will demonstrate a glucose concentration response in the presence of blood and interstitial fluid matrix components, the ability of RECEPTORS LLC to complete the Phase II goal, and all other statements in this press release other than historical facts are ”forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995.
Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and VeriChip’s actual results could differ materially from expected results. These risks and uncertainties include the Company’s ability to successfully develop and commercialize the microchip, the market acceptance of the microchip, the Company’s and RECEPTORS’ ability to develop a microchip, the validity, scope and enforceability of the Company’s patents and those related to the microchip, the protection afforded by the Company’s patents and those related to the microchip, the Company’s ability to complete the development phases in certain time frames, government regulations relating to the microchip, the Company’s ability to fund the continued development of the microchip, the timing and success of submission, acceptance and approval of required regulatory filings; as well as certain other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on February 12, 2009, under the caption ”Risk Factors.” The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Additional Information and Where to Find It
On September 8, 2009, VeriChip and Steel Vault issued a joint press release announcing the signing of an Agreement and Plan of Reorganization, among VeriChip, Steel Vault and VeriChip Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of VeriChip (the ”Acquisition Subsidiary”), pursuant to which the Acquisition Subsidiary will be merged with and into Steel Vault, with Steel Vault surviving and becoming a wholly-owned subsidiary of VeriChip (the ”Merger”). Upon the consummation of the Merger, each outstanding share of Steel Vault’s common stock will be converted into 0.5 shares of VeriChip common stock.
In connection with the Merger, VeriChip filed with the Securities and Exchange Commission (”SEC”) a Registration Statement on Form S-4 that will contain a Joint Proxy Statement/Prospectus of VeriChip and Steel Vault. Investors and security holders are urged to read the Registration Statement and the Joint Proxy Statement/Prospectus carefully because they contain important information about VeriChip, Steel Vault and the proposed transaction.
The Joint Proxy Statement/Prospectus and other relevant materials (when they become available), and any other documents filed with the SEC, may be obtained free of charge at the SEC’s web site (www.sec.gov). In addition, investors and security holders may obtain a free copy of other documents filed by VeriChip or Steel Vault by directing a written request, as appropriate, to VeriChip at 1690 South Congress Avenue, Suite 200 Delray Beach, Florida 33445, Attention: Investor Relations, or to Steel Vault at 1690 South Congress Avenue, Suite 200 Delray Beach, Florida 33445, Attention: Investor Relations. Investors and security holders are urged to read the Joint Proxy Statement/Prospectus and the other relevant materials before making any voting or investment decision with respect to the proposed transaction.
VeriChip, Steel Vault and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction.
Information regarding the interests of these directors and executive officers in the proposed transaction will be included in the Joint Proxy Statement/Prospectus referred to above. Additional information regarding the directors and executive officers of VeriChip is also included in VeriChip’s Form 10-K, which was filed with the SEC on February 12, 2009. Additional information regarding the directors and executive officers of Steel Vault is also included in Steel Vault’s proxy statement (Form DEF 14A) for the 2009 annual meeting of Steel Vault’s stockholders, which was filed with the SEC on February 9, 2009, as amended. These documents are available free of charge at the SEC’s website (www.sec.gov) and by contacting Investor Relations at the addresses above. Contacts:
VeriChip Corporation, Delray Beach
Allison Tomek, 561-805-8008 atomek@verichipcorp.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Link to: http://www.prisonplanet.com/one-mainframe-to-rule-them-all.html
The Greatest Story Never Told Vaccine-A uncovers a story of betrayal—the betrayal of the men and women who serve in the armed forces, the betrayal of medical ethics, and the betrayal of the American people by military and civilian leaders sworn to defend and protect. Veteran journalist Gary Matsumoto shows that the worst friendly-fire incident in military history came from something no soldier had any reason to think would harm him: a vaccine administered by the military’s own medics. When troops went to the Middle East to fight the Gulf War in 1991 and the Iraq War in 2003, many—perhaps thousands—received an experimental anthrax vaccine instead of the FDA-approved vaccine. Without their knowledge or consent, the U. S. government used them as human guinea pigs in a massive medical experiment that went disastrously wrong.
In 1978, the Pentagon began developing an anthrax vaccine of unsurpassed safety and purity. Soon, however, military scientists learned that their new vaccine, though pure, was also ineffective. To remedy this they added an oil called squalene—an “adjuvant”—to stimulate the immune system. What the scientists didn’t know, but should have known, is that squalene causes autoimmune diseases: chronic and even life-threatening diseases like lupus erythematosus, crippling arthritis, and multiple sclerosis. Matsumoto reveals that even very recently, squalene-laced “vaccine A” continues to be secretly injected into Army, Navy, and Air Force personnel. Vaccine-A introduces you to the victims of this experimental mistake. We meet an Army sergeant whose skin became so diseased that doctors, in a desperate attempt to cure him, removed every square inch of skin from his body. We read the story of a Green Beret colonel who, suffering walking blackouts that left him unable to find his way home, was misdiagnosed for years and even accused of bleeding himself to distort his laboratory tests. We see that others, including a man whose cerebellum literally shrank until he could no longer walk straight or write his name, were often told they had psychiatric disorders or were accused of malingering.
We also meet the doctors, Pamela and Kevin Asa, who uncovered the truth about these illnesses despite strong opposition by the Pentagon and National Institutes of Health. Finally, Vaccine-A warns about what is yet to happen. The military, the vaccine’s manufacturer, and the Department of Health and Human Services all refuse to admit that any experiment took place or that they are responsible for its devastating effects. Instead, they continue to inject the same anthrax vaccine into Iraq War soldiers and plan a release for civilian consumption soon. Should these vaccines become widely used, Matsumoto predicts, we should expect a man-made epidemic of unprecedented size. About the Author
Gary Matsumoto, a journalist based in New York City, has reported from thirty-two different countries on five continents, covered two wars and five popular uprisings, and won ten journalism awards. He has been the London Bureau Manager and Chief Foreign Correspondent for NBC Radio News; a National Correspondent for NBC’s Weekend Today Show and Senior Correspondent for the Fox News Channel. As a broadcaster, he has covered events ranging from the toppling of the Communist Party in Eastern Europe to Desert Storm, the Tiananmen Square massacre to the death of Princess Diana. He has written about the anthrax letter attacks for the Washington Post and Science magazine. His 1998 article in Vanity Fair was the first to draw the connection between the anthrax vaccine and Gulf War Syndrome.
Ch 3 – The Greatest Story Never Told
For the past 17 years, the Army has been working on a new anthrax vaccine that contains no anthrax, and is made with an ingredient that it does not want to name. That ingredient is called squalene. Squalene is an oil. Without it, the new vaccine will not work any better than the old one. In fact, for all intents and purposes, without squalene the new vaccine is the old one. What makes squalene so important is its proven ability to stimulate a strong response from the immune system. That is something the main ingredient of the new vaccine, the now ultra-purified protein secreted by the anthrax microbe—recombinant protective antigen—cannot do by itself. It is too weak.
